Last reviewed · How we verify

NCT05199155

Use of a Nerve Regeneration Conduit (NerVFIX®) in the Treatment of Nerve Section of the Wrist

Terminated Phase 2 Last updated 14 November 2024
What this trial tests

Phase 2 trial testing NerVFIX in Nerve Injury in 12 participants. Terminated before completion.

Timeline
8 December 2020
Primary endpoint
13 August 2024
13 August 2024

Quick facts

Lead sponsorTBF Genie Tissulaire
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12
Start date8 December 2020
Primary completion13 August 2024
Estimated completion13 August 2024
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

TBF Genie Tissulaire — full company profile →

Who can join

Adults 18 to 65, any sex, with Nerve Injury or Nerve Lesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this open, multicenter trial is to assess the impact of a nerve regeneration conduit made of allogeneic artery or vein from umbilical cord lining on the regeneration of wrist nerve.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Engineering neural recovery: Micro/nano-structured materials for nerve regeneration.
    Zhang H, Sha J, Cao S, Feng J, et al · · 2025 · cited 1× · PMID 41322153 · DOI 10.1016/j.mtbio.2025.102538

Verify or expand the search:

Other recruiting trials for Nerve Injury

Currently open trials in the same condition.

Other TBF Genie Tissulaire trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05199155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing